An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner. Learn more about your ad choices. Visit megaphone.fm/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Eyewire News: The Podcast
Breaking News From the ESCRS Congress in London (Part 1 of 2)
FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA
FDA Sets PDUFA Date for Investigational Glaucoma Eye Drop
EyePoint Misses Primary Endpoint in Phase 3 Trial But Sees Promise After Analysis
Get summaries like this every morning.
Free AI-powered recaps of Eyewire News: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.